WO2007110079A8 - Targeted delivery of fgfr ligands into the brain - Google Patents

Targeted delivery of fgfr ligands into the brain

Info

Publication number
WO2007110079A8
WO2007110079A8 PCT/DK2007/000152 DK2007000152W WO2007110079A8 WO 2007110079 A8 WO2007110079 A8 WO 2007110079A8 DK 2007000152 W DK2007000152 W DK 2007000152W WO 2007110079 A8 WO2007110079 A8 WO 2007110079A8
Authority
WO
WIPO (PCT)
Prior art keywords
peptide sequence
compound
treatment
brain
fgfr
Prior art date
Application number
PCT/DK2007/000152
Other languages
French (fr)
Other versions
WO2007110079A3 (en
WO2007110079A2 (en
Inventor
Elisabeth Bock
Vladimir Berezin
Vladislav V Kiselyov
Original Assignee
Enkam Pharmaceuticals As
Elisabeth Bock
Vladimir Berezin
Vladislav V Kiselyov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enkam Pharmaceuticals As, Elisabeth Bock, Vladimir Berezin, Vladislav V Kiselyov filed Critical Enkam Pharmaceuticals As
Publication of WO2007110079A2 publication Critical patent/WO2007110079A2/en
Publication of WO2007110079A8 publication Critical patent/WO2007110079A8/en
Publication of WO2007110079A3 publication Critical patent/WO2007110079A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/825—Metallothioneins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a compound consisting of metallothionein (MT) and a peptide sequence, wherein said peptide sequence and metallotionein are bound to each other via a non-covalent bond. A peptide sequence comprised by the compound is a biologically active short peptide sequence which comprises at most 25 amino acid residues. The peptide sequence is capable of binding to and modulating activity of a functional cell receptor, in particular fibroblast growth factor receptor (FGFR). The invention relates to pharmaceutical compositions comprising such compound or such peptide sequence and use of the compound, peptide sequence and pharmaceutical composition for treatment of conditions and diseases where modulating activity of FGFR is beneficial for treatment. In preferred embodiments the use is for treatment of conditions and diseases of the brain including conditions requiring stimulating brain cell proliferation, differentiation and/or survival, stimulating neural plasticity associated with learning and memory, modulating adhesion and motility of cells, in particular cancer cells. The compound of the invention is capable of penetrating the blood brain barrier (BBB).
PCT/DK2007/000152 2006-03-29 2007-03-28 Targeted delivery of fgfr ligands into the brain WO2007110079A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600450 2006-03-29
DKPA200600450 2006-03-29

Publications (3)

Publication Number Publication Date
WO2007110079A2 WO2007110079A2 (en) 2007-10-04
WO2007110079A8 true WO2007110079A8 (en) 2007-12-13
WO2007110079A3 WO2007110079A3 (en) 2008-03-20

Family

ID=38541454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2007/000152 WO2007110079A2 (en) 2006-03-29 2007-03-28 Targeted delivery of fgfr ligands into the brain

Country Status (1)

Country Link
WO (1) WO2007110079A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101619093B (en) * 2009-05-26 2011-12-07 中国人民解放军第三军医大学野战外科研究所 Polypeptide with function of promoting activity of fibroblast growth factor receptor 3 and screening method and application thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190083A1 (en) * 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
AU2013271609A1 (en) * 2012-06-05 2014-12-18 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychiatric disorders or symptoms thereof using NCAM peptide mimetics
CN113559249B (en) * 2021-07-19 2023-08-22 中国人民解放军陆军军医大学第一附属医院 Application of deoxyribonuclease I in preparation of medicine for treating and preventing traffic hydrocephalus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2457164A1 (en) * 2001-08-17 2003-02-27 Enkam Pharmaceuticals A/S Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells
AUPS295802A0 (en) * 2002-06-13 2002-07-04 University Of Tasmania Metallothionein based neuronal therapeutic and therapeutic methods
CN101027320A (en) * 2004-06-18 2007-08-29 恩卡姆医药公司 FGFR binding peptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101619093B (en) * 2009-05-26 2011-12-07 中国人民解放军第三军医大学野战外科研究所 Polypeptide with function of promoting activity of fibroblast growth factor receptor 3 and screening method and application thereof

Also Published As

Publication number Publication date
WO2007110079A3 (en) 2008-03-20
WO2007110079A2 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
US20220265763A1 (en) Polypeptide-polymer conjugates and methods of use thereof
HK1118210A1 (en) Compositions and methods for treating cardiac conditions
EP2412727A3 (en) Metallothionein-derived peptide fragments
WO2006073889A3 (en) Sustained delivery of pdgf using self-assembling peptide nanofibers
DE69734607T2 (en) LONG-ACTING MEDICAMENTS AND MEDICAMENTS CONTAINING THEM
WO2007102686A8 (en) Peptides having activities of insulin like growth factor-1 and their uses
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
CN104168955A (en) Calcimimetics and methods for their use
MX2010004547A (en) Pegylation by the dock and lock (dnl) technique.
ATE424848T1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE CONTROLLED RELEASE OF BIOLOGICAL ACTIVE INGREDIENTS
RU2007106075A (en) COMPOSITIONS AND METHODS OF APPLICATION OF ANGIOPOETIN-LIKE PROTEIN 4
EP2484768A3 (en) Mucosal or enteral administration of biologically active macromolecules
WO2004027064A3 (en) Ghrh analogues
WO2006056984A3 (en) Chelating and binding chemicals to a medical implant
WO2007062060A3 (en) Methods and compositions using substance p to promote wound healing
EA200702523A1 (en) APPLICATION OF ERYTHROPOIETHIN IN LOW DOSAGE FOR STIMULATION OF ENDOTHELIAL CELLS PRECONDENTS, AND ALSO FOR REGENERATION OF ORGANS AND SLOWING PROGRESSION OF DAMAGES OF FINAL ORGANS
RU2011105821A (en) THERAPEUTIC DOSING OF NEUREGULIN OR ITS SEQUENCE FOR THE TREATMENT OR PREVENTION OF HEART FAILURE
WO2007110079A3 (en) Targeted delivery of fgfr ligands into the brain
JP2005506300A5 (en)
WO2005055948A3 (en) Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders
WO2007019860A3 (en) Gdnf derived peptides
WO2006010084A3 (en) A system for delivering therapeutic agents into living cells and cell nuclei
NO20063937L (en) Composition comprising L-serine, L-isoleucine, folic acid and trace elements for the treatment of psoriasis
WO2007071248A3 (en) Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
EP1997826A3 (en) Synthetic ligands for immunoglobulins and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07711293

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07711293

Country of ref document: EP

Kind code of ref document: A2